JAK2 p.V617F is known to promote thrombosis by inducing a pro-inflammatory endothelial environment, particularly relevant in low-flow venous sites such as cerebral sinuses and splanchnic veins, supporting MPN screening in these patients. Here, JAK2 is linked to myeloproliferative disorder.